Lilly, Galapagos halt trials as coronavirus deepens impact on drug research

Lilly, Galapagos halt trials as coronavirus deepens impact on drug research

Source: 
BioPharma Dive
snippet: 

Eli Lilly became the first large pharmaceutical company to announce delays to its clinical trials as a result of the outbreak of the novel coronavirus. Biotechs Galapagos and ObsEva also postponed studies as the fast-spreading pandemic continued to take its toll on clinical research.